Betamethasone for Antenatal Surfactant Stimulation
Administer intramuscular betamethasone as a combination formulation of betamethasone sodium phosphate and betamethasone acetate (not a single salt), given as 2 doses of 12 mg each, 24 hours apart. 1
Recommended Formulation and Dosing
The Society for Maternal-Fetal Medicine (SMFM) provides Grade 1A evidence recommending the specific betamethasone formulation used in the landmark ALPS trial 1:
- Formulation: Betamethasone sodium phosphate combined with betamethasone acetate (dual-salt formulation) 1
- Dose: 12 mg intramuscularly per injection 1
- Schedule: Two doses administered 24 hours apart 1
- Route: Intramuscular injection only 1
Why This Specific Formulation Matters
The dual-salt formulation provides both immediate and sustained-release properties 2:
- Betamethasone phosphate: Rapidly absorbed, providing immediate fetal exposure 2
- Betamethasone acetate: Slowly released over time, maintaining therapeutic levels 2
Research demonstrates that the betamethasone acetate component is critical for optimal lung maturation, with studies showing that betamethasone acetate alone at lower doses (0.125 mg/kg) achieves similar lung maturation to the standard dual-formulation while reducing total fetal betamethasone exposure 2. However, clinical guidelines have not yet adopted single-salt formulations, and the standard dual-salt preparation remains the evidence-based recommendation 1.
Clinical Application by Gestational Age
Late Preterm (34 0/7 to 36 6/7 weeks)
- Offer treatment to singleton pregnancies at high risk of delivery within 7 days and before 37 weeks 1
- Use the standard 2-dose regimen of 12 mg betamethasone (dual-salt) 24 hours apart 1
- Contraindicated in women with pregestational diabetes mellitus due to increased risk of severe neonatal hypoglycemia 1
Earlier Preterm (<34 weeks)
- Same formulation and dosing regimen applies 1
- Evidence shows greater efficacy in male versus female infants, though treatment is recommended regardless of fetal sex 3
Important Clinical Caveats
Do not reduce the dose: A 2022 randomized trial of 3,141 neonates demonstrated that half-dose betamethasone (single 11.4 mg injection) failed to show non-inferiority compared to the full two-dose regimen for preventing respiratory distress syndrome (20.0% vs 17.5%, risk difference 2.4%, 95% CI -0.3 to 5.2) 4. The full dose remains necessary despite theoretical concerns about neurodevelopmental effects 4.
Avoid in low-risk patients: Do not administer to women with low likelihood of delivery before 37 weeks, as the risks may outweigh benefits in this population 1
Timing considerations: Recent administration (within 10 days of delivery) shows superior outcomes compared to earlier exposure in high-risk late preterm populations, though this does not support routine repeat dosing 5
Formulation specificity: The FDA-approved betamethasone product contains both betamethasone sodium phosphate and betamethasone acetate in a fixed combination 6. Do not substitute with single-salt preparations or dexamethasone, as these have different pharmacokinetic profiles 2